Vitamin D modulates biliary fibrosis in ABCB4-deficient mice by unknown
ORIGINAL ARTICLE
Vitamin D modulates biliary fibrosis in ABCB4-deficient mice
Katrin Hochrath • Caroline S. Stokes •
Ju¨rgen Geisel • Marion J. Pollheimer •
Peter Fickert • Steven Dooley • Frank Lammert
Received: 2 February 2014 / Accepted: 18 May 2014 / Published online: 21 June 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Purpose Impaired vitamin D receptor signaling represents
an aggravating factor during liver injury, and recent studies
suggest that vitamin D might exert a protective role in
chronic hepatobiliary diseases. We hypothesized that vita-
min D supplementation would ameliorate liver fibrosis in
ATP-binding cassette transporter B4 knockout (Abcb4-/-)
mice as a preclinical model of sclerosing cholangitis.
Methods Abcb4-/- and wild-type mice were fed a regular
chow diet (600 IU vitamin D/kg food) or diets with lower
(100 IU/kg) and higher (2,400 IU/kg) vitamin D concen-
trations for 12 weeks. Serum 25-hydroxyvitamin D con-
centrations were measured by chemiluminescence
immunoassays. Liver injury and biliary fibrosis were
assessed by liver enzyme activities, histopathology and
hepatic collagen contents. Hepatic mRNA expression of
markers for fibrosis, vitamin D and bile acid metabolism
were analyzed by quantitative PCR.
Results Different vitamin D concentrations were
observed depending on genotype and diet group, with
Abcb4-/- mice on the control diet showing lower vitamin
D concentrations compared to wild-type mice. Abcb4-/-
animals on the low vitamin D diet demonstrated the most
advanced liver fibrosis and highest hepatic collagen con-
tents. Feeding Abcb4-/- mice a high vitamin D diet enri-
ched serum vitamin D levels, lowered liver enzyme
activities, altered expression levels of profibrogenic genes
and ameliorated, in part, liver injury.
Conclusions This is the first report to demonstrate that
fibrogenesis in the established Abcb4-/- model is influ-
enced by vitamin D supplementation. Since vitamin D
modulates sclerosing cholangitis in vivo, we speculate that
sufficient vitamin D intake might improve liver damage
and induce antifibrotic effects in chronic cholestasis in
humans.
Keywords ABC transporters  Cholecalciferol  Chronic
cholangitis  Fibrogenesis  Liver injury
Introduction
Vitamin D deficiency occurs in up to 90 % of patients with
chronic liver diseases, irrespective of the underlying eti-
ology of liver injury [1, 2]. Moreover, in these patients, low
vitamin D levels are associated with increased grades of
necroinflammation and stages of fibrosis and a heightened
mortality risk [3–6]. Despite these observations, and in
particular the inverse correlation between vitamin D levels
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and the severity of liver diseases, to date few studies have
investigated the beneficial and adverse effects of vitamin D
supplementation in chronic liver diseases [7–9]. Therefore,
data regarding the efficacy of vitamin D supplementation
are still lacking, and preclinical models for assessing the
effects of vitamin D are needed.
Vitamin D is a steroid hormone with pleiotropic effects
that undergoes hydroxylation in liver and kidney [6]. The
major circulating form, 25-hydroxyvitamin D, is bound to
vitamin D-binding protein, whereas effects of 1a,25-di-
hydroxyvitamin D on target genes in many organs are
mediated by a ligand-activated nuclear receptor, the vita-
min D receptor (VDR) [10], which forms a heterodimer
with the retinoid X receptor (RXR) to modulate processes
and networks ranging from immune responses to mineral
homoeostasis (Supplementary Fig. 1). In the liver, VDR
expression is restricted to non-parenchymal cells and bili-
ary epithelial cells [11]. Besides activation of VDR by
vitamin D, lithocholic acid and its derivatives have been
demonstrated to function as VDR ligands and activators
[12]. Furthermore, regulation of bile acid synthesis and
enzymes responsible for bile acid detoxification are influ-
enced by vitamin D-VDR-signaling [13–15]. These find-
ings collectively point to a potential modulatory role of
vitamin D-VDR signaling in biliary-type liver injury.
Hence, we hypothesized that vitamin D supplementation
ameliorates liver fibrosis in vivo by phenotyping Abcb4
(ATP-binding cassette transporter, subfamily B, member 4)
knockout (Abcb4-/-, also known as Mdr2-/-) mice, an
established and highly reproducible model of sclerosing
cholangitis [16–18]. Abcb4-/- mice lack the hepatocana-
licular phosphatidylcholine floppase ABCB4 and develop
sclerosing cholangitis and liver fibrosis [19]. The disease
caused by mutations of the orthologous human gene is
called progressive familial intrahepatic cholestasis (PFIC
type 3), which resembles primary sclerosing cholangitis.
Materials and methods
Animals
FVB/N-Abcb4tm1bor mice and FVB/NJ control mice were
obtained from the Jackson Laboratory (Bar Harbor, ME,
USA). The mice were housed and bred in individually
ventilated cages with a 12-h light-dark cycle under incan-
descent lighting free from UVB radiation. Temperature and
humidity were regulated at 22 ± 1 C and 55 ± 5 %,
respectively. Water and food were provided ad libitum.
Mice were genotyped by polymerase chain reaction (PCR)
of tail DNA using neo (50-CTT GGG TGG AGA GGC
TAT TC-30; 50-AGG TGA GAT GAC AGG AGA TC-30)
and Abcb4 (50-CAC TTG GAC CTG AGG CTG TG; TCA
GGA CTC CGC TAT AAC GG-3) specific primer pairs.
The PCR reaction included PCR buffer (Applied Biosys-
tems, Darmstadt, Germany), 2 mM MgCl2, 10 lM dNTPs,
10 lM primer, 1.25 U Taq DNA polymerase (Invitrogen,
Darmstadt, Germany) and 20–100 ng DNA in 25-ll reac-
tions. PCR cycling conditions were 94 C/30 s, 55 C/60 s
and 72 C/30 s for 35 cycles and a final extension step of
10 min at 72 C.
The animal experiments were performed with permis-
sion from the federal state of Saarland according to §8 of
the German Law for the Protection of Animals and the
Directive 2010/63/EU of the European Parliament. All
institutional and national guidelines for the care and use of
laboratory animals were followed.
Diets
The vitamin D diets were commenced after weaning in the
4th week of age, coinciding with the initiation of liver
pathology including sclerosing cholangitis, which at this
point is not yet fully developed [20]. Wild-type controls
and Abcb4-/- mice of both sexes were divided into three
groups, with each receiving a different diet: The control
group was fed a regular chow diet containing 600 IU
vitamin D (cholecalciferol)/kg food, which is based on the
established nutrient requirements for laboratory mice [21].
The low vitamin D group obtained a diet with 100 IU
vitamin D/kg, and the high vitamin D diet group was fed a
diet enriched with 2,400 IU vitamin D/kg. All diets were
given for 12 weeks. With the exception of vitamin D
content, all three diets were otherwise equal in nutrient
composition and total energy, and were obtained from
Altromin (Lage, Germany; see Supplementary Tables 1, 2
and 3 for detailed dietary composition). In total, 113 ani-
mals were analyzed, with a minimum of 15 mice per
genotype and diet group. Table 1 provides the number of
animals analyzed per genotype, sex and diet group. Food
intake was controlled by monitoring weekly food con-
sumption per cage and did not differ (3–4 g/day) among
the groups. Survival rates were 100 %.






Female Male Female Male
Low vitamin D diet (100 IU/kg) 11 9 6 9
Control vitamin D diet (600 IU/
kg)
10 7 10 9
High vitamin D diet (2,400 IU/kg) 12 11 9 11
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Phenotypic characterization of biliary fibrosis
For histopathological evaluation, liver samples were pre-
served in 4 % neutral-buffered formaldehyde solution at
4 C and embedded in paraffin. Paraffin sections (2 lm)
were stained with haematoxylin-eosin (H&E) or Sirius red
for the detection of collagen. The stages of liver fibrosis
and relative collagen areas were assessed by a pathologist
blinded to the study protocol using a semiautomatic system
for image analysis (Stingray F146C IRF Medical camera,
00 type progressive scan CCD, Germany) and HistoQuant
image morphometry software (3DHistech, Budapest,
Hungary). Hepatic fibrosis was staged (F-score) using a
scale adapted from the Batts and Ludwig as well as Ishak
scoring systems [22, 23]. The F-scores are subdivided into
five classes: 0 = no fibrosis; 1 = scatter periportal and
perineoductular fibrosis; 2 = periportal, perineoductular
fibrosis; 3 = periportal, perineoductular fibrosis with por-
tal–portal septa; 4 = complete cirrhosis.
Relative collagen content was determined as the mean
percentage of the collagen-stained area to the whole area
(field of view). Therefore, we screened representative
microscopic fields (magnification, 1009), which were
randomly chosen from each liver section (avoiding arteries
of [100 lm diameter) after setting a threshold capturing
Sirius red-stained areas of collagen. In addition, collagen in
liver was quantified by colorimetric measurement of the
collagen-specific amino acid hydroxyproline, as described
previously [24, 25].
Serum biochemical assays
Blood was collected from the inferior vena cava after har-
vesting. Samples were left for 10 min at room temperature in
darkness and centrifuged for 20 min at 2,0009g. Serum was
stored at -80 C until analysis. Serum calcium concentra-
tions, alanine aminotransferase (ALT), aspartate amino-
transferase (AST) and alkaline phosphatase (AP) activities
were measured in the Cobas 8000 analyzer (Roche Diag-
nostics, Mannheim, Germany) by standardized methods
following the recommendations of the International Feder-
ation of Clinical Chemistry. Serum 25-hydroxyvitamin D
concentrations were determined using the chemilumines-
cence immunoassay LIAISON 25 OH Vitamin D TOTAL
Assay (DiaSorin, Stillwater, MN, USA).
Gene expression analyses by quantitative real-time
PCR
Hepatic mRNA expression levels of individual genes were
determined by quantitative real-time PCR (qPCR) (TaqMan,
Applied Biosystems) using 1 lg RNA for reverse transcrip-
tion and 18S RNA as endogenous control, with one cycle at
95 C for 10 min, followed by 45 cycles at 95 C/30 s and
60 C/60 s. The sex-specific expression levels were calcu-
lated by the DDct-method [26] in relation to counterpart wild-
type controls (e.g., DDctCol1a2 = DctCol1a2 Abcb4
-/- female
on low vitamin D diet-meanDctCol1a2 wild-type female on low
vitamin D diet). The relative quotient (RQ, 2-DDct) for each
sample was normalized to sex-specific wild-type mice fed the
control diet. The TaqMan (Applied Biosystems) expression
assay IDs were Col1a2, Mm01165187_m1; Cramp,
Mm00438285_m1; Cyp2r1, Mm01159413_m1; Cyp7a1,
Mm00484150_m1; Cyp8b1, Mm00501637_s1; Cyp27a1,
Mm00470430_m1; Tgfb1, Mm03024053_m1; Timp1,
Mm00441818_m1; Vdr, Mm00437297_m1.
Immunofluorescence microscopy for cytokeratin 19
and E-cadherin
Double immunofluorescence staining for cytokeratin 19
(CK19) and E-cadherin was performed on an acetone-fixed
(-20 C, 10 min) cryosection of liver tissue (4–6 animals
per genotype and diet group). CK19 was detected using a
monoclonal rabbit anti-Troma-III antibody (1:500) [27]. In
addition, slides were incubated with a monoclonal rabbit
antibody anti-E-cadherin (1:200; no. 3195, Cell Signaling
Technology, Danvers, MA, USA). Secondary antibodies
were conjugated to fluor 488-goat anti-rabbit (1:100) or
tetramethylrhodamine isothiocyanate 565-anti-rabbit anti-
body (1:50) [19].
Statistics
The results were analyzed using SPSS 20.0 (IBM, Ehnin-
gen, Germany). Quantitative data are presented as
means ± standard errors (SE) or median and ranges, as
appropriate. All data were analyzed for the effects of diet
and genotype. Means were compared with Student’s t tests
or one-way analyses of variance (ANOVA), followed by
post hoc Bonferroni correction. The medians of non-para-
metric data were compared with Mann–Whitney U or
Kruskal–Wallis tests, respectively. Two-way ANOVA was
applied to assess the interaction of diet and sex after
exclusion of extreme values. Correlation coefficients were
calculated according to Pearson or Spearman as appropri-
ate. p values \ 0.05 were considered significant.
Results
Vitamin D supplementation exerts no toxic effects
in Abcb4-/- mice
After weaning, all mice continued to develop normally and
displayed no obvious signs of developmental or behavioral
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abnormalities. Body weight and liver-to-body weight ratios
were not affected by dietary composition, with the excep-
tion of female Abcb4-/- mice on the high vitamin D diet
displaying increased body weight compared to knockout
mice on the control diet (24.6 ± 0.9 g vs. 20.2 ± 0.9 g,
p \ 0.01). Serum calcium levels were slightly higher in
Abcb4-/- mice as compared to wild-type controls in all
dietary groups, and no hypercalcemia was induced (Sup-
plementary Fig. 2).
Vitamin D serum concentrations depend on genotype,
sex and diet
As shown in Fig. 1, mice displayed different serum vitamin
D concentrations depending on genotype and diet group. On
the low vitamin D diet, both strains displayed serum vitamin
D levels \10 ng/ml. Abcb4-/- mice on the control diet
showed significantly (p \ 0.01) lower vitamin D concen-
trations compared to FVB/NJ wild-type mice on this diet
(38.4 ± 1.9 vs. 46.8 ± 1.7 ng/ml). In contrast, Abcb4-/-
mice on the high vitamin D diet demonstrated significantly
(p \ 0.001) increased vitamin D levels in comparison to
wild-type counterparts (67.2 ± 2.4 vs. 42.0 ± 2.3 ng/ml).
The vitamin D concentrations in female mice were signif-
icantly (p \ 0.001) higher than in male mice in the high
vitamin D group, and a significant (p \ 0.01, two-way
ANOVA) interaction between sex and diet was observed for
vitamin D levels but not for other phenotypes.
Vitamin D supplementation influences hepatic fibrosis
in Abcb4-/- mice
Figure 2 illustrates that the quantification of hepatic col-
lagen contents revealed a significant (p \ 0.01) increase in
Abcb4-/- mice in all three diet groups as compared to
controls. Hepatic collagen contents were highest in
Abcb4-/- mice receiving the vitamin D-deficient diet and
displayed a dose-related trend towards lower levels in
knockout mice on the regular and the high vitamin D diets.
In contrast, no impact of diet on hepatic collagen levels
was detected in wild-type mice (Fig. 2).
Histopathological staging of liver fibrosis revealed no
fibrosis (F0) in wild-type mice. Contrary, Abcb4-/- mice
progressed to fibrosis stage F3. Abcb4-/- animals on the
low vitamin D diet demonstrated significantly (p \ 0.001)
higher fibrosis scores (median F3, range F2–F3) compared
with knockout mice fed the control or the high vitamin D
diets (high vitamin D diet: median F2, range F1–F3; con-
trol diet: median F2, range F0–F3).
Panel A of Fig. 3 shows that these histopathological
observations were reflected by the relative collagen areas,
as determined after Sirius red staining. Representative liver
sections stained with Sirius red are shown in Fig. 3b. As
expected, we observed genotype-dependent differences,
with increased collagen areas in Abcb4-/- mice as com-
pared to wild-type mice. Collagen areas were significantly
(p \ 0.01) larger in Abcb4-/- mice receiving the low
vitamin D diet in comparison to those on the control diet
(2.47 %, range 0.93–4.57 vs. 2.08 %, range 0.05–2.62).
The lowest collagen areas in Abcb4-/- mice were deter-
mined in animals fed the high vitamin D diet (2.03 %,
range 0.69–4.31). Interestingly, wild-type mice on the high
vitamin D diet also showed significantly (p \ 0.01)
reduced collagen areas (0.18 %, range 0.09–0.35) in
comparison to mice on diets with lower vitamin D con-
centrations (control diet: 0.38 %, range 0.10–1.27; low
vitamin D diet: 0.31 %, range 0.10–1.08).
Fig. 1 Mean Serum 25-hydroxyvitamin D concentrations in
Abcb4-/- and wild-type mice fed different vitamin D diets for
12 weeks. **p \ 0.01, ***p \ 0.001
Fig. 2 Mean hepatic collagen contents (±SE) as determined via the
collagen-specific amino acid hydroxyproline in Abcb4-/- and wild-
type mice fed different vitamin D diets for 12 weeks. *p \ 0.05,
**p \ 0.01, ***p \ 0.001
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Serum parameters for liver damage and cholestasis
(ALT, AST, AP) were significantly elevated in Abcb4-/-
compared to corresponding wild-type mice in all diet
groups (Fig. 4). Notably, enzymatic activities of both ALT
and AST in Abcb4-/- mice significantly decreased on the
high vitamin D diet as compared to knockout mice fed the
control diet. Wild-type mice receiving the high vitamin D
diet displayed elevated ALT activities in comparison to
those on the control diet (68 U/l, range 37–314 vs. 48 U/l,
range 11–77; p \ 0.01). AP activities did not differ
between diet groups in either knockout or wild-type mice
(Fig. 4c).
Dietary vitamin D affects hepatic expression
of profibrogenic genes in Abcb4-/- mice
Panel A of Fig. 5 illustrates that hepatic steady-state
mRNA expression levels of collagen type I (Col1a2) were
significantly (p \ 0.001) higher in ABCB4-deficient mice
as compared to wild-type controls, irrespective of the diet.
Timp1 expression increased significantly (p \ 0.001) in
Abcb4-/- mice fed the control or the high vitamin D diets,
but not in animals fed the low vitamin D diet as compared to
corresponding wild-type mice (Fig. 5b). Panel C of Fig. 5
shows that a similar trend was observed for transforming
growth factor (Tgf)-b1 expression, with significantly
(p \ 0.05) reduced levels in Abcb4-/- mice on the low
vitamin D diet as compared to the control diet. Tgf-b1
expression correlated significantly (q = 0.92, p \ 0.01)
with expression of Vdr in Abcb4-/- mice.
Diet and genotype modify the hepatic expression of Vdr
and vitamin D hydroxylases
The hepatic gene expression of Vdr was increased in ABCB4-
deficient mice compared with the corresponding wild-type
controls in all diet groups. Similar to Tgf-b1 and Timp1
expression, vitamin D-deficient Abcb4-/- mice displayed
Fig. 3 (a) Median relative
collagen contents (with 1.5
interquartile ranges) as
determined after Sirius red
staining and (b) representative
liver sections after Sirius red
staining of livers from
Abcb4-/- and wild-type mice
fed different vitamin D diets for
12 weeks. *p \ 0.05,
**p \ 0.01, ***p \ 0.001.
(Color figure online)
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lower expression levels of Vdr as compared to Abcb4-/- mice
on the control diet (Fig. 6a). Panel B of Fig. 6 illustrates that
hepatic gene expression of the antimicrobial peptide cath-
elicidin (Cramp) was increased in Abcb4-/- animals on
control and low vitamin D diets, whereas knockout mice fed
the high vitamin D diet did not differ from wild-type animals.
The highest Cramp expression levels were observed in vita-
min D-deficient Abcb4-/- mice.
Fig. 4 Serum liver enzyme activities. a Alanine aminotransferase
(ALT), b aspartate aminotransferase (AST) and c alkaline phospha-
tase (AP) activities in Abcb4-/- and wild-type mice fed different
vitamin D diets. *p \ 0.05, **p \ 0.01, ***p \ 0.001
Fig. 5 Relative hepatic mRNA expression levels of profibrogenic
genes. a Collagen type I, a2-chain (Col1a2), b tissue inhibitor of
matrix metalloproteinase 1 (Timp1) and c transforming growth factor-
b1 (Tgf-b1) in Abcb4-/- and wild-type mice fed different vitamin D
diets for 12 weeks. Data are normalized based on the expression of
wild-type mice fed the vitamin D control diet (600 IU/kg food).
*p \ 0.05, **p \ 0.01, ***p \ 0.001
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As circulating vitamin D levels depend on the Abcb4
genotype and diet (Fig. 1), we assessed expression differ-
ences of the major vitamin D hydroxylase Cyp2r1 and
Cyp27a1 in liver. The mRNA levels of both enzymes were
markedly increased in Abcb4-/- mice challenged with low
and high vitamin D diets (data not shown). The expression
of the genes Cyp7a1 and Cyp8b1, encoding the rate-lim-
iting enzymes for bile acid synthesis and conversion to
cholic acid, respectively, tended to decrease in Abcb4-/-
mice on diets with higher vitamin D contents, but no sig-
nificant differences were observed (data not shown).
Vitamin D supplementation does not appear
to influence hepatic adherens junction integrity
As determined by double immunofluorescence microscopy
(Fig. 7), genotype-specific changes of bile duct integrity
could be observed. Abcb4-/- animals from all vitamin D
diet groups displayed an increase in ductular proliferation,
as shown by the higher number of K19-positive cholan-
giocytes and overexpression of E-cadherin. At the hepa-
tocyte level, a diffuse E-cadherin expression within the
liver lobe was detected in Abcb4-/- mice (Fig. 7d–f),
which contrasted with the findings in wild-type controls.
However, an influence of dietary vitamin D intake on
changes in the E-cadherin distribution pattern on the
hepatocyte or even bile duct level was not apparent in
either strain.
Discussion
In this study, we examined the modulatory effects of die-
tary vitamin D supplementation on biliary fibrosis in vivo
in Abcb4-/- mice. The following major results were
demonstrated: (1) vitamin D deficiency is associated with
increased collagen accumulation and fibrogenesis in this
preclinical model; (2) a vitamin D-sufficient diet amelio-
rates chronic liver injury; and (3) high dose vitamin D
supplementation exerts a further benefit only by reduction
of aminotransferase activities. Taken together, these find-
ings suggest that low vitamin D levels aggravate liver
fibrosis, but supranormal vitamin D levels have no additive
antiinflammatory or -fibrotic effects in Abcb4-/- mice.
This may indicate that vitamin D deficiency should be
avoided to decrease the risk of progressive fibrosis in
chronic cholangitis and that an adequate vitamin D intake
has, at least to some extent, antiinflammatory and anti-
fibrotic effects. These observations are relevant for future
translational studies, because chronic cholestatic liver
injury in humans is frequently accompanied by vitamin D
deficiency [7, 28]. More specifically, Abcb4-/- mice
receiving the low vitamin D diet developed more advanced
stages of fibrosis as compared to mice consuming diets
with higher vitamin D contents. Of note, maximum vitamin
D supplementation did not further improve the fibrosis
scores in our model, but in comparison to the control group
it ameliorated hepatocellular damage, as illustrated by
lower serum aminotransferase activities. These observa-
tions are also reflected by enhanced hepatic collagen
accumulation in Abcb4-/- mice with vitamin D deficiency,
whereas the lowest collagen contents were observed in
mice receiving the high vitamin D diet. The mRNA
expression analyses did not identify differences in collagen
expression, pointing to vitamin D-dependent post-tran-
scriptional regulatory mechanisms. On the other hand,
in vitro studies and a rat model of toxin-induced hepatic
fibrosis have demonstrated possible antifibrotic effects of
vitamin D supplementation through diminished hepatic
stellate cell (myofibroblast) activation and collagen
expression [29–31]. These different observations might be
due to the diverse experimental setups, in particular
Fig. 6 Relative hepatic mRNA expression levels of the (a) vitamin D
receptor (Vdr) and (b) cathelicidin (Cramp) genes in Abcb4-/- and
wild-type mice fed different vitamin D diets for 12 weeks. Data are
normalized based on the expression of wild-type mice fed the vitamin
D control diet (600 IU/kg food). *p \ 0.05, **p\0.01, ***p\0.001
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homogeneous cell cultures versus heterogeneous cell pop-
ulations from total liver, given that in cholestatic disorders
portal fibroblasts are predominantly responsible for hepatic
collagen deposition [32].
Despite identical dietary intake, Abcb4-/- mice dem-
onstrated lower vitamin D serum concentrations on control
chow diet as compared to wild-type mice. Serum vitamin D
levels increased markedly in Abcb4-/- mice receiving the
high vitamin D diet, whereas it remained constant in wild-
type mice. These findings allude to a potential dysregula-
tion of intestinal vitamin D uptake. Additionally, we
observed higher expression of the vitamin D activating
enzymes Cyp2r1 and Cyp27a1 in livers of ABCB4-defi-
cient mice on the high vitamin D diet. Vitamin D levels are
regulated through degradation via 24-hydroxylase, and
vitamin D induces the expression of this enzyme, thus
controlling its own catabolism [33, 34]. Of note, bile acids
such as lithocholic acid have been shown to decrease this
stimulatory effect of vitamin D and influence a broad
spectrum of signaling pathways via the nuclear receptors
VDR, FXR and PXR [35–38]. In fact, minor changes in
bile salt composition have been shown to affect hepatic
fibrogenesis in ABCB4-deficient mice [39], although the
expression of the genes encoding the rate-limiting enzymes
for bile salt synthesis (Cyp7a1) and conversion to the
hydrophobic cholic acid (Cyp8b1) showed no major dif-
ferences across the groups. Further studies, however, would
be required to elucidate the molecular mechanisms
underlying the genotype-diet interactions.
The expression levels of the fibrosis markers Col1a2,
Timp1 and Tgf-b1 did not strictly correlate with the
severity of liver injury and fibrosis. Some of these dis-
crepancies could be related to the fact that we measured
mRNA levels in total liver, although vitamin D might exert
specific effects on different hepatic cell populations.
Altered vitamin D-VDR signaling, which has been reported
in cholestatic conditions, was corroborated in this study, as
illustrated by increased Vdr expression in ABCB4-deficient
as compared to wild-type mice. Furthermore, Vdr expres-
sion was reduced in Abcb4-/- mice on the low vitamin D
diet, and these animals displayed the highest fibrosis
scores. Recently, elegant mechanistic studies have dem-
onstrated that the activation of VDR antagonizes TGF-b-
induced recruitment of SMAD3 via co-occupation of reg-
ulatory sites in key profibrogenic genes (including
COL1A2, TIMP1 and TGFB1) in the presence of TGF-b
[31]. In this context it is interesting to note that in com-
parison to Abcb4-/- mice on control diet, our data show
lower Tgf-b1 expression levels both in vitamin D defi-
ciency and upon excess dietary supplementation,
Fig. 7 Double immunofluorescence staining for K19 (in green) and
E-cadherin (in red) of livers from Abcb4-/- and wild-type mice fed
different vitamin D diets for 12 weeks. At the hepatocyte level,
predominant E-cadherin expression occurs in zone I of the liver lobe
in wild-type animals (indicated by white arrows, panels a–c), whereas
diffuse E-cadherin expression is present in Abcb4-/- mice (panels d–
f). bd bile duct, pv portal vein. (Color figure online)
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illustrating the interaction of vitamin D and TGF-b sig-
naling in the setting of biliary inflammation and fibrosis.
Given the potential antiinflammatory effects of vitamin
D, we also assessed the hepatic expression of the antimi-
crobial peptide cathelicidin (Cramp) [40]. Since the vita-
min D response element is absent in the murine Cramp
promoter (in contrast to humans) [41], we conclude that the
decrease of Cramp expression upon vitamin D supple-
mentation to levels observed in healthy controls is more
likely to reflect the amelioration of hepatic inflammation
than direct effects on Cramp. Further investigations into
the regulation of antimicrobial peptides in sclerosing cho-
langitis would be interesting but were beyond the scope of
this study.
To protect parenchymal liver cells from toxic bile com-
pounds, epithelial cells form a physical barrier by apical
junctional complexes (tight junction and adherens junc-
tion). Distinct functional and morphological alterations of
these junctional complexes have been described in chole-
stasis in both mice and humans [19, 42]. Since vitamin D
has been shown to be involved in the regulation of apical
junctional complexes in other organs [43–45], Firrincieli
et al. [46] recently investigated the role of VDR in the
maintenance of bile duct integrity in mice with biliary-type
injury. Their study demonstrated altered E-cadherin stain-
ing and loss of cell adhesion in biliary epithelial cells in
Vdr-/- mice subjected to bile duct ligation [46]. Therefore,
we also assessed hepatic adherens integrity in our model,
which revealed genotype-specific differences in biliary
epithelial cell proliferation and E-cadherin staining. How-
ever, vitamin D-dependent effects could not be substanti-
ated. Nevertheless, this does not exclude the possibility that
truncated E-cadherin, which was shown to be present in
higher amounts in Vdr-/- mice [46], might be relevant.
In conclusion, our findings indicate that vitamin D
modulates biliary injury and fibrogenesis in vivo and that
the severity of biliary fibrosis in Abcb4-/- mice is influ-
enced by vitamin D status. In this model, vitamin D defi-
ciency appears to aggravate liver fibrosis; however, the
beneficial effects of vitamin D supplementation are limited.
We speculate that excess vitamin D supplementation does
not fully protect against liver fibrosis, but an adequate
vitamin D intake abates hepatic injury and confers anti-
fibrotic effects in patients with cholestatic liver diseases.
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